Kindred Biosciences Inc. has received approval from the U.S. Food & Drug Administration for Mirataz (mirtazapine transdermal ointment) for the management of weight loss in cats.
Mirtazapine, which blocks specific serotonin and histamine receptors that play a role in appetite and nausea, demonstrated a 3.9 percent increase in body weight in cats with unintended weight loss in as little as 14 days, according to San Francisco-based Kindred.
To help improve owner and patient compliance, Mirataz will be available in a topical formulation applied to the inner pinna of a cat’s ear. Research shows daily topical application for 14 days resulted in measurable plasma concentrations of mirtazapine in cats, the manufacturer stated.
Mirataz offers the confidence of a product approved by the U.S. Food & Drug Administration Center for Veterinary Medicine, convenience of transdermal application, Good Manufacturing Practice (cGMP) production quality, known stability, manufacturer technical support, and a practical way to manage feline weight loss without administration of oral medication, according to Valentine S. Williams, DVM, DACVS, director of veterinary affairs at Kindred Biosciences.
Commercial sales are expected to begin in summer 2018.